N-Zyme Biomedical raises $4.6M Series A (United States, Jul 2026)
$4.6M
US$4.6 Million Series AGenerated social card
Headline
N-Zyme Biomedical Closes US$4.6 Million Series A Financing to Advance Clinical Development - Times Argus
About
N-Zyme Biomedical is focused on developing novel therapies for reflux disease, specifically through its pepsin inhibitor platform. The company aims to address significant unmet medical needs in conditions like laryngopharyngeal reflux and gastroesophageal reflux disease. This funding round will accelerate their Phase 2 clinical programs and further their innovative approach to treatment.
Article summary
N-Zyme Biomedical Closes US$4.6 Million Series A Financing to Advance Clinical Development Times Argus
Founder
Franco Vigile
Co-Founder and Chief Executive Officer
Investors
Related rounds
| Jul 25, 2026 | Braiding Robot | $7.0M | — | United States |
| Jul 25, 2026 | Casana | $46.0M | Series B | United States |
| Jul 24, 2026 | World Foundation | $52.5M | — | United States |
| Jul 24, 2026 | Petra Labs | $5.2M | — | United States |